Clinical Trials UnitUpcoming Studies ATRI TRC-DS Study The aim of Trial-Ready Cohort- Down Syndrome (TRC-DS) is to enrol non-demented adults between the ages of 25-55 with Down syndrome (DS) into a trial ready cohort (TRC). Participants enrolled in this study will undergo longitudinal cognitive and clinical assessment, imaging, and genetic and biomarker testing. Researchers will then analyse the relationships between AD biomarkers and these measures to design Alzheimer’s disease prevention trials ideally suited for people with DS. Not yet recruiting. Recruitment to begin Q2 2025 Current Studies STRIDES study This study will explore the use of gait speed as both a vital sign and digital clinical biomarker in a diverse population of older adults. This research will focus on gait speed variability and its associated health implications, including cognitive decline, sarcopenia, frailty, and an increased risk of falls. One part of this study will examine the benefits of targeted exercise interventions on improving gait speed. Currently open for recruitment Patients who can participate - Those aged 65 years, or older
- Able to walk independently or with assistive devices
Study duration - Single visit lasting up to 90 minutes
or - Two visits lasting up to 90 minutes, for those participants engaged in a longitudinal exercise programme
What does involvement entail? - Brief medical review including past medical history, medications and a history of falls
- Cognitive performance tests
- Gait speed measurements
- Sarcopenia assessments
- Frailty evaluation
Further information on the procedures, tests and visits can be obtained from the study team Recent Studies EVOKE/EVOKE+ study A phase III research study investigating the superiority of oral semaglutide vs placebo on the change in cognition and function, in people with mild cognitive impairment due to Alzheimer’s disease. Active, recruitment closed ENBIND study Digital Gait and Speech, and Novel Biomarkers as Indicators of Cognitive Decline in Midlife Type 2 Diabetes Mellitus. Waves 1 and 2 completed Completed Studies 20-AVP-786-307 study Phase III study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's type. Study Completed VINCI-AD study Non-invasive vagus nerve stimulation therapy for patients with mild cognitive impairment. This therapy is looking to investigate the potential role for transcutaneous vagus nerve stimulation for cognitive enhancement in Alzheimer’s disease. GAS-Cog (Canary) study Analysis of gait and speech characteristics as objective measures of cognitive performance in healthy aging, mild cognitive impairment, and early-stage dementia. The aim of this study is to explore the application of artificial intelligence-based analysis of gait and speech as a digital marker of cognitive decline. EU201 study Phase II sponsored study investigating the effectiveness and safety of the novel medicine T817MA on brain levels of tau protein, in parallel with changes in imaging, electroencephalogram, and cognition, in patients with mild cognitive impairment or dementia due to Alzheimer’s disease. Sense-Cog Study A collaboration with St James’s hospital, this study looked to investigate whether visual and hearing interventions had a positive effect on Cognition in patients with mild to moderate AD. EPOCH study Our first AD clinical trial (EPOCH study) began in Aug 2016 and it continued until Feb 2018. Phase III international industry-sponsored study investigating the effect of a novel investigational medicine on brain levels of amyloid protein, in parallel with changes in imaging and cognition, in people with mild cognitive impairment due to AD Since the Unit started in 2016 the Cognitive Clinical Trials Unit (CCTU) in TUH has become one of Irelands leading dementia clinical trials unit participating in key international clinical trials for novel treatments. For the first time Irish patients were recruited in a large global drug trial for prevention of Alzheimer’s disease. This was an important milestone for our hospital, and for Ireland, as it was the first time that Irish patients with memory difficulties were given the opportunity to trial medication that could potentially delay or halt progression of their symptoms. Our current portfolio of studies reflects the mission of the CCTU: “To develop interventions that enable prevention, better detection, cure, and enhance care for people living with dementia”. This mission is realised with the support of colleagues in both TUH and TCD, partner sites around Ireland, and international and industry collaborators. The CCTU is a member of the Dementia Trials Ireland network of clinical trials sites, and Professor Kennelly is co-lead of the DTI network. Meet the teamThe CCTU is a multi-disciplinary research team supported by Professor Seán Kennelly with colleagues from the departments of geriatric medicine and neurology in TUH. Ruth Ennis is the Dementia Research & Trials Project Manager ruth.ennis@tuh.ie Jasmine Joseph is our Research Nurse jasmine.joseph@tuh.ie The research team also includes specialist physicians, Advanced Nurse Practitioners, psychologists, and occupational therapists. Contact Dementia Research Office: +353 1 414 3213 |